Integration Management: Governance & Operational PMO with OSICS NetworkTHE OSICS NETWORK
The Importance of Post-Acquisition Management to Maximize Value Creation
The success of an acquisition in the pharmaceutical or biotech sector is not measured at the time of signing. The post-acquisition phase is decisive in turning the identified value potential into tangible gains. Without structured and rigorous management, even the best synergies remain theoretical, optimization projects stall, and the promised financial performance fails to materialize.
In the demanding environment of pharma and biotech—where supply chains are complex, quality standards are uncompromising, and industrial processes are rigid—integration management requires specialized expertise. Without it, local teams risk becoming misaligned, optimization plans stagnate, and value creation objectives are compromised.
That is why OSICS offers comprehensive support in post-M&A governance and operational PMO. We help Private Equity funds secure the integration of their acquisitions by structuring strategic governance and orchestrating operational execution. Our approach ensures that every post-acquisition initiative translates into measurable results, and that every identified lever is effectively activated.
OSICS Methodology for Structuring Integration Governance
From deal closure, establishing robust governance is an immediate priority. At OSICS, we quickly design a governance architecture tailored to the asset’s specifics and the investor’s strategic ambitions. This involves clear alignment between the Board, Executive Team, and Middle Management of the acquired entity.
Our approach relies on a detailed RACI matrix to define roles and responsibilities, ensuring that every stakeholder understands precisely what is expected. We help formalize the strategic integration objectives—targeted industrial synergies, cost reduction goals, quality optimization plans, productivity improvements. These objectives are translated into precise operational targets linked to predefined performance indicators (KPIs).
The governance we establish is designed to be agile and responsive. It is built around regular steering committees, clear reporting tools, and seamless communication across all organizational levels. In pharma/biotech environments, where quality and regulatory constraints impose additional requirements, this adapted governance enables integration to be managed without compromising compliance or industrial stability.
Operational PMO: Securing the Execution of Transformation Plans
Beyond strategic governance, successful integration requires flawless execution on the ground. OSICS Network deploys dedicated Operational PMO structures, specifically calibrated to manage transformation programs in pharmaceutical and biotech industries.
Our Operational PMO acts as the nerve center of the post-acquisition project. It coordinates TIPs (Transformation & Integration Plans) across multiple workstreams—supply chain, production, quality, regulatory compliance, human resources—ensuring overall coherence and tracking progress against set objectives. Each workstream is associated with precise deliverables, clear deadlines, and performance KPIs validated with project sponsors.
One of OSICS’s key differentiators lies in our ability to manage an Operational PMO truly focused on industrial operations. Our teams understand the challenges of manufacturing efficiency, regulatory compliance, and quality certification. This enables us to anticipate technical or organizational obstacles before they slow integration—and to secure value creation within the investor’s expected timeline.
A Direct Lever to Accelerate Value Creation
Structured post-acquisition management delivers tangible results across the entire asset portfolio. OSICS experience shows that an effective Operational PMO accelerates industrial synergy capture and enhances profitability far more quickly than when execution is left solely to local initiatives.
In practice, our projects have achieved operational cost reductions of 10% to 20% within the first 18 months post-acquisition—through rapid activation of synergies identified during Due Diligence. Transformation plans led by our PMO have also delivered average OEE (Overall Equipment Effectiveness) improvements of 5 to 10 points, faster quality compliance across critical sites, and reduced governance gaps that could impact profitability.
The ability to manage change centrally while respecting local realities is a major differentiator. It ensures not only that financial objectives are met, but also that operational, human, and regulatory risks are controlled throughout this critical phase of integration.
Looking to Better Frame Your Strategic Challenges?
At OSICS, every consulting mission is grounded in a precise understanding of your business goals, sector dynamics, and operational realities. Our tailored approach helps organizations make the right decisions—at the right time, with the right partners.
Why Entrust the Management of Your Integration to the OSICS Network
OSICS combines the methodological rigor of major consulting firms (and some of our experts come from them) with hands-on industrial expertise specific to the pharmaceutical and biotech sectors. Our approach is built on the direct experience of consultants who have led plants, production lines, supply chains, or quality functions in highly complex and regulated environments.
We know that post-deal execution is where acquisition value is built.
That’s why we offer governance and Operational PMO services tailored to each asset, each strategy, and each team dynamic. Our goal is to turn your ambitious integration plans into concrete, measurable, and sustainable results.
Engaging OSICS to manage your integration means benefiting from a team that understands your financial objectives, masters your industrial constraints, and brings the necessary experience to secure and accelerate value creation across your Pharma/Biotech assets.